M&A Deal Summary |
|
|---|---|
| Date | 2018-09-07 |
| Target | Novate Medical |
| Sector | Medical Products |
| Buyer(s) | BTG |
| Deal Type | Add-on Acquisition |
| Deal Value | 20M USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1948 |
| Sector | Medical Products |
| Employees | 1,182 |
| Revenue | 823M USD (2018) |
BTG plc which develops and commercializes products used in minimally-invasive procedures targeting cancer and vascular diseases, as well as acute care pharmaceuticals. BTG has three key businesses, the largest of which is its Interventional Medicine portfolio which encompasses several peripheral interventional product lines. The interventional oncology franchise includes the TheraSphere® Y-90 radiotherapy microspheres and the GALIL™ cryoablation system, used to treat patients with liver, kidney, and other cancers. More than 840,000 people are expected to be diagnosed with liver cancer in 2018, and that number is expected to grow to 1.1 million by 2030. Kidney cancer is among the 10 most common cancers in both men and women.
| DEAL STATS | # |
|---|---|
| Overall | 6 of 6 |
| Sector (Medical Products) | 5 of 5 |
| Type (Add-on Acquisition) | 4 of 4 |
| State (Louisiana) | 1 of 1 |
| Country (United States) | 4 of 4 |
| Year (2018) | 1 of 1 |
| Size (of disclosed) | 4 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-10-05 |
Roxwood Medical
Redwood City,, California, United States Roxwood Medical, Inc. is an innovative provider of advanced cardiovascular specialty catheters used in the treatment of patients with severe coronary and peripheral artery disease. Roxwood's anchoring catheters (CenterCross®, CenterCross® Ultra, MultiCross®) and microcatheters (MicroCross®) offer options for physicians in the crossing of complex lesions and arterial blockages. |
Buy | $80M |
